We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

48 hedge funds and large institutions have $43.3M invested in Carisma Therapeutics in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more call options, than puts

Call options by funds: $467K | Put options by funds: $357K

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

2% more funds holding

Funds holding: 47 → 48 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.45% less ownership

Funds ownership: 2.42% → 1.97% (-0.45%)

46% less capital invested

Capital invested by funds: $80.2M → $43.3M (-$36.9M)

Holders
48
Holders Change
+1
Holders Change %
+2.13%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
12
Reduced
10
Closed
11
Calls
$467K
Puts
$357K
Net Calls
+$110K
Net Calls Change
-$569K

Top Buyers

Rank Fund Capital Flow
1
KCM
Kingdon Capital Management
New York
+$1.27M
2
Millennium Management
Millennium Management
New York
+$430K
3
PVI
Pura Vida Investments
New York
+$319K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$286K
5
SSA
Schonfeld Strategic Advisors
New York
+$275K

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$14.6M
2
NC
Nexthera Capital
New York
-$2.53M
3
SFM
Sphera Funds Management
Israel
-$1.35M
4
DCM
Driehaus Capital Management
Illinois
-$465K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$181K
Name Holding Trade Value Shares
Change 		Change in
Stake
Brown Advisory
26
Brown Advisory
Maryland
$30K – – –
FT
27
Fiduciary Trust
Massachusetts
$28K – – –
Invesco
28
Invesco
Georgia
$25K -$861 -27 -3%
BCM
29
Bayesian Capital Management
New York
$20K +$22.3K +700 New
Creative Planning
30
Creative Planning
Kansas
$19K +$1.28K +40 +6%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$15K -$28.4K -890 -63%
LC
32
Lindbrook Capital
California
$14K +$15.9K +500 New
HFM
33
Hartford Financial Management
Connecticut
$6K – – –
Morgan Stanley
34
Morgan Stanley
New York
$6K +$128 +4 +2%
CHP
35
Cable Hill Partners
Oregon
$3K -$4.78K -150 -60%
AG
36
Advisor Group
Arizona
$3K – – –
CG
37
Cutler Group
California
$3K +$2.87K +90 +273%
Wells Fargo
38
Wells Fargo
California
$2K -$4.98K -156 -64%
UBS Group
39
UBS Group
Switzerland
$2K -$4.66K -146 -66%
APA
40
American Portfolios Advisors
New York
$1.42K – – –
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$1K -$8.04K -252 -91%
TWA
42
TCI Wealth Advisors
Arizona
$1K -$159 -5 -17%
Citigroup
43
Citigroup
New York
$1K – – –
ACA
44
Avoro Capital Advisors
New York
– -$14.6M -340,000 Closed
NC
45
Nexthera Capital
New York
– -$2.53M -58,850 Closed
SFM
46
Sphera Funds Management
Israel
– -$1.35M -31,500 Closed
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
– -$181K -4,214 Closed
Alyeska Investment Group
48
Alyeska Investment Group
Illinois
– -$115K -2,665 Closed
MA
49
MYDA Advisors
New York
– -$108K -2,500 Closed
PAG
50
Private Advisor Group
New Jersey
– -$53K -1,226 Closed
1
2
3

CARM Hedge Fund Activity: Q4 2018 in Review

48 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2018, worth a combined $43.3M — down 46% from $80.2M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CARM positions and 11 closed out — a net gain of 1 holder — while 12 added to existing stakes and 10 trimmed.

The largest buyer was Kingdon Capital Management, adding an estimated $1.27M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $14.6M sold.

  • 48 institutional investors held Carisma Therapeutics (CARM) as of Q4 2018, up from 47 in Q3 2018.
  • Funds reported $43.3M of Carisma Therapeutics stock for Q4 2018, down 46% quarter-over-quarter.
  • 12 funds opened new Carisma Therapeutics positions in Q4 2018 and 11 closed out, a net change of +1 holder.
  • The largest Carisma Therapeutics buyer in Q4 2018 was Kingdon Capital Management, an estimated $1.27M added.
  • The largest Carisma Therapeutics seller in Q4 2018 was Avoro Capital Advisors, an estimated $14.6M sold.

Based on aggregated 13F filings for Q4 2018.